Effects of Curcumin-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles in MDA-MB231 Human Breast Cancer Cells

Sharma, Ankur; Hawthorne, Susan; Jha, Saurabh; Jha, Niraj Kumar; Kumar, Dhruv; Girgis, Samuel; Goswami, Vineet Kumar; Gupta, Gaurav; Singh, Sachin Kumar; Dureja, Harish; Chellappan, Dinesh Kumar; Dua, Kamal

doi:10.2217/nnm-2021-0066

Cited by 30 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PLGA-NPs loaded with CUR were developed utilizing a modified solvent evaporation process, resulting in increased EE and prolonged drug release. 76 Furthermore, the NPs notably decreased cellular viability, migration, and invasion to the MDA-MB-231 cell line. 76 Treatment of TNBC poses significant obstacles in cancer treatment, mostly attributed to the limited availability of drug delivery methods capable of efficiently targeting malignant areas.…”

Section: Nanostructured Lipid Carriers (Nlcs)mentioning

confidence: 96%

“…The PLGA-NPs loaded with CUR were developed utilizing a modified solvent evaporation process, resulting in increased EE and prolonged drug release . Furthermore, the NPs notably decreased cellular viability, migration, and invasion to the MDA-MB-231 cell line …”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…76 Furthermore, the NPs notably decreased cellular viability, migration, and invasion to the MDA-MB-231 cell line. 76 Treatment of TNBC poses significant obstacles in cancer treatment, mostly attributed to the limited availability of drug delivery methods capable of efficiently targeting malignant areas. The riboflavin analogue CSRf was loaded into PLGA-NPs as CSRf-PLGA-NPs.…”

Section: Nanostructured Lipid Carriers (Nlcs)mentioning

confidence: 99%

See 2 more Smart Citations

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) is a malignant neoplasm that begins in the breast tissue. After skin cancer, BC is the second most common type of cancer in women. At the end of 2040, the number of newly diagnosed BC cases is projected to increase by over 40%, reaching approximately 3 million worldwide annually. The hormonal and chemotherapeutic approaches based on conventional formulations have inappropriate therapeutic effects and suboptimal pharmacokinetic responses with nonspecific targeting actions. To overcome such issues, the use of nanomedicines, including liposomes, nanoparticles, micelles, hybrid nanoparticles, etc., has gained wider attention in the treatment of BC. Smaller dimensional nanomedicine (especially 50–200 nm) exhibited improved in vivo effectiveness, such as better tissue penetration and more effective tumor suppression through enhanced retention and permeation, as well as active targeting of the drug. Additionally, nanotechnology, which further extended and developed theranostic nanomedicine by incorporating diagnostic and imaging agents in one platform, has been applied to BC. Furthermore, hybrid and theranostic nanomedicine has also been explored for gene delivery as anticancer therapeutics in BC. Moreover, the nanocarriers’ size, shape, surface charge, chemical compositions, and surface area play an important role in the nanocarriers’ stability, cellular absorption, cytotoxicity, cellular uptake, and toxicity. Additionally, nanomedicine clinical translation for managing BC remains a slow process. However, a few cases are being used clinically, and their progress with the current challenges is addressed in this Review. Therefore, this Review extensively discusses recent advancements in nanomedicine and its clinical challenges in BC.

show abstract

Section: Nanostructured Lipid Carriers (Nlcs)mentioning

confidence: 96%

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Section: Nanostructured Lipid Carriers (Nlcs)mentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

“…In comparison to MCF‐7 cells cultivated as monolayers, MCF‐7 mammospheres exhibited higher amounts of Hh pathway members. They also discovered a link between the expression of smoothened ( SMO )/ GLI family zinc finger 1 ( Gli1 ) and the BCSC markers CD44 + CD24 − in BCSCs (Li, Wang, & Xiao, 2021; Sharma et al, 2021). Through a p21‐mediated suppression of Hh‐Gli signaling, resveratrol and curcumin work together to trigger apoptosis in cigarette smoke condensate‐altered breast epithelial cells (Li, Zhou, et al, 2021).…”

Section: Signaling Pathways In Pathogenesis Of Bcmentioning

confidence: 99%

Role of Medicinal plant‐derived Nutraceuticals as a potential target for the treatment of breast cancer

Alharbi

Almalki

Makeen

et al. 2022

Journal of Food Biochemistry

Self Cite

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most challenging cancers to treat, accounting for many cancer‐related deaths. Over some years, chemotherapy, hormone treatment, radiation, and surgeries have been used to treat cancer. Unfortunately, these treatment options are unsuccessful due to crucial adverse reactions and multidrug tolerance/resistance. Although it is clear that substances in the nutraceuticals category have a lot of anti‐cancer activity, using a supplementary therapy strategy, in this case, could be very beneficial. Nutraceuticals are therapeutic agents, which are nutrients that have drug‐like characteristics and can be used to treat diseases. Plant nutraceuticals categorized into polyphenols, terpenoids, vitamins, alkaloids, and flavonoids are part of health food products, that have great potential for combating BC. Nutraceuticals can reduce BC's severity, limit malignant cell growth, and modify cancer‐related mechanisms. Nutraceuticals acting by attenuating Hedgehog, Nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB), Notch, and Wnt/β‐catenin signaling are the main pathways in controlling the self‐renewal of breast cancer stem cells (BCSCs). This article reviews some important nutraceuticals and their modes of action, which can be very powerful versus BC. Practical applications Nutraceuticals' importance to the control and diagnosis of breast cancer is undeniable and cannot be overlooked. Natural dietary compounds have a wide range of uses and have been used in traditional medicine. In addition, these natural chemicals can enhance the effectiveness of other traditional medicines. They may also be used as a treatment process independently because of their capacity to affect several cancer pathways. This study highlights a variety of natural chemicals, and their mechanisms of action, routes, synergistic effects, and future potentials are all examined.

show abstract

“…As a representative example, poly (lactic-co-glycolic acid) (PLGA) NPs are an extensive choice in the biomedical field, thanks to their excellent biodegradability and biocompatibility [ 76 , 77 ]. For example, Cur-loaded PLGA NPs were prepared using the double-emulsion solvent evaporation method, which could inhibit the migration of MDA-MB231 cells in vitro [ 78 ]. However, some urgent issues, such as partial drug loss, poor in vivo stability, slow release, and premature drug release of PLGA NPs, need to be solved so as to further enhance PLGA NPs as hydrophobic drug delivery nanoplatforms in practical clinical applications.…”

Section: Curcumin Nanoformulationsmentioning

confidence: 99%

Modulation of Macrophages Using Nanoformulations with Curcumin to Treat Inflammatory Diseases: A Concise Review

et al. 2022

View full text Add to dashboard Cite

Curcumin (Cur), a traditional Chinese medicine extracted from natural plant rhizomes, has become a candidate drug for the treatment of diseases due to its anti-inflammatory, anticancer, antioxidant, and antibacterial activities. However, the poor water solubility and low bioavailability of Cur limit its therapeutic effects for clinical applications. A variety of nanocarriers have been successfully developed to improve the water solubility, in vivo distribution, and pharmacokinetics of Cur, as well as to enhance the ability of Cur to polarize macrophages and relieve macrophage oxidative stress or anti-apoptosis, thus accelerating the therapeutic effects of Cur on inflammatory diseases. Herein, we review the design and development of diverse Cur nanoformulations in recent years and introduce the biomedical applications and potential therapeutic mechanisms of Cur nanoformulations in common inflammatory diseases, such as arthritis, neurodegenerative diseases, respiratory diseases, and ulcerative colitis, by regulating macrophage behaviors. Finally, the perspectives of the design and preparation of future nanocarriers aimed at efficiently exerting the biological activity of Cur are briefly discussed.

show abstract

Effects of Curcumin-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles in MDA-MB231 Human Breast Cancer Cells

Cited by 30 publications

References 26 publications

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Role of Medicinal plant‐derived Nutraceuticals as a potential target for the treatment of breast cancer

Modulation of Macrophages Using Nanoformulations with Curcumin to Treat Inflammatory Diseases: A Concise Review

Contact Info

Product

Resources

About